We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Phibro (PAHC) to Report Q4 Earnings: What's in the Cards?
Read MoreHide Full Article
Phibro Animal Health Corporation (PAHC - Free Report) is scheduled to report fourth-quarter fiscal 2021 results on Aug 25, after the opening bell.
In the third quarter of fiscal 2021, the company reported earnings per share of 34 cents. The metric surpassed the Zacks Consensus Estimate by 3%. The company missed estimates in one of the trailing four quarters and surpassed the same in three, the average negative surprise being 8.70%.
Let's take a look at how things are shaping up prior to this announcement.
Factors at Play
In third-quarter fiscal 2021, Phibro registered growth in the nutritional specialties business driven by strong international growth in dairy products. This is likely to have continued through the fiscal fourth quarter as well, thus adding to the top line. The company’s Vaccine business is expected to have witnessed growth in the to-be reported quarter on the back of consistently growing domestic volumes as well as increasing demand in the Asia-Pacific region. Moreover, the company, during its last earnings call, noted the receipt of European Union GMP approval for the new vaccine facility in Sligo, Ireland. The company has also finalized an agreement that adds two early stage oral care products as well. These developments are expected to have contributed to segmental growth in the fiscal fourth quarter, thus adding to the top line.
However, challenging economic conditions in Eastern Europe may have adversely impacted the company’s vaccine business during the fiscal fourth quarter.
Phibro Animal Health Corporation Price and EPS Surprise
Currently, the company is focused on expanding its footprint in the poultry, swine and cattle industries, in both domestic and international markets. Phibro is working actively to expand in the cattle markets in the United States, specifically in Mexico and Brazil, as well as in Canada, Australia and South Africa. The company also recently signed an agreement with Virbac to distribute latter’s generic DRAXXIN in the Canadian market. The company has licensed a unique derma care compound for treatment of atopic dermatitis in dogs. These developments are likely to have contributed to fourth-quarter fiscal 2021 revenue growth.
Further, similar to the last-reported quarter, Phibro’s Mineral Nutrition arm is expected to have registered growth in the fourth quarter of fiscal 2021 as well, led by favorable product pricing, thus adding to the top line.
During the third quarter of fiscal 2021, Phibro registered growth in its Performance Products segment driven by strong demand for copper-based products, which translated into increased unit volumes. This is likely to have continued through fourth-quarter fiscal 2021 as well, thus boosting revenue growth.
The Estimate Picture
For fourth-quarter fiscal 2021, the Zacks Consensus Estimate for earnings per share is pegged at 32 cents. This implies an improvement of 88.2% from the prior-year quarter’s reported figure.
What Our Model Suggests
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) along with a positive Earnings ESP has higher chances of beating estimates. However, this is not the case here as you can see:
Earnings ESP: Phibro has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle.
Abercrombie & Fitch Company (ANF - Free Report) has an Earnings ESP of +6.14% and a Zacks Rank of 1, at present. The company is slated to release second-quarter 2021 results on Aug 26.
Burlington Stores, Inc. (BURL - Free Report) has an Earnings ESP of +15.26% and a Zacks Rank of 1, at present. The company is slated to release second-quarter 2021 results on Aug 26.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Phibro (PAHC) to Report Q4 Earnings: What's in the Cards?
Phibro Animal Health Corporation (PAHC - Free Report) is scheduled to report fourth-quarter fiscal 2021 results on Aug 25, after the opening bell.
In the third quarter of fiscal 2021, the company reported earnings per share of 34 cents. The metric surpassed the Zacks Consensus Estimate by 3%. The company missed estimates in one of the trailing four quarters and surpassed the same in three, the average negative surprise being 8.70%.
Let's take a look at how things are shaping up prior to this announcement.
Factors at Play
In third-quarter fiscal 2021, Phibro registered growth in the nutritional specialties business driven by strong international growth in dairy products. This is likely to have continued through the fiscal fourth quarter as well, thus adding to the top line. The company’s Vaccine business is expected to have witnessed growth in the to-be reported quarter on the back of consistently growing domestic volumes as well as increasing demand in the Asia-Pacific region. Moreover, the company, during its last earnings call, noted the receipt of European Union GMP approval for the new vaccine facility in Sligo, Ireland. The company has also finalized an agreement that adds two early stage oral care products as well. These developments are expected to have contributed to segmental growth in the fiscal fourth quarter, thus adding to the top line.
However, challenging economic conditions in Eastern Europe may have adversely impacted the company’s vaccine business during the fiscal fourth quarter.
Phibro Animal Health Corporation Price and EPS Surprise
Phibro Animal Health Corporation price-eps-surprise | Phibro Animal Health Corporation Quote
Currently, the company is focused on expanding its footprint in the poultry, swine and cattle industries, in both domestic and international markets. Phibro is working actively to expand in the cattle markets in the United States, specifically in Mexico and Brazil, as well as in Canada, Australia and South Africa. The company also recently signed an agreement with Virbac to distribute latter’s generic DRAXXIN in the Canadian market. The company has licensed a unique derma care compound for treatment of atopic dermatitis in dogs. These developments are likely to have contributed to fourth-quarter fiscal 2021 revenue growth.
Further, similar to the last-reported quarter, Phibro’s Mineral Nutrition arm is expected to have registered growth in the fourth quarter of fiscal 2021 as well, led by favorable product pricing, thus adding to the top line.
During the third quarter of fiscal 2021, Phibro registered growth in its Performance Products segment driven by strong demand for copper-based products, which translated into increased unit volumes. This is likely to have continued through fourth-quarter fiscal 2021 as well, thus boosting revenue growth.
The Estimate Picture
For fourth-quarter fiscal 2021, the Zacks Consensus Estimate for earnings per share is pegged at 32 cents. This implies an improvement of 88.2% from the prior-year quarter’s reported figure.
What Our Model Suggests
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) along with a positive Earnings ESP has higher chances of beating estimates. However, this is not the case here as you can see:
Earnings ESP: Phibro has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle.
Advance Auto Parts, Inc. (AAP - Free Report) has an Earnings ESP of +13.22% and a Zacks Rank of 2, at present. The company is slated to release second-quarter fiscal 2021 results on Aug 24. You can see the complete list of today’s Zacks #1 Rank stocks here.
Abercrombie & Fitch Company (ANF - Free Report) has an Earnings ESP of +6.14% and a Zacks Rank of 1, at present. The company is slated to release second-quarter 2021 results on Aug 26.
Burlington Stores, Inc. (BURL - Free Report) has an Earnings ESP of +15.26% and a Zacks Rank of 1, at present. The company is slated to release second-quarter 2021 results on Aug 26.